The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market By The End Of 2030?
The next-generation sequencing (ngs)-based molecular diagnostics market has shown robust expansion over recent years. It is projected to increase from $2.26 billion in 2025 to $2.43 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.6%. The historical growth of this market was primarily driven by factors such as the rise in genetic disorder testing, advancements in high-throughput sequencing, increased awareness of molecular diagnostics, broader adoption within clinical laboratories, and continuous technological enhancements in sequencing reagents.
The next-generation sequencing (ngs)-based molecular diagnostics market is anticipated to experience substantial expansion over the coming years. Its valuation is projected to reach $3.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.3%. This projected growth is driven by several factors, including the incorporation of AI and machine learning into diagnostics, the broadening of cloud-based genomic platforms, the creation of portable and point-of-care sequencing technologies, an increase in personalized medicine applications, and strategic alliances between diagnostics and biotechnology companies. Key trends influencing this period encompass AI-assisted molecular diagnostics, platforms for cloud genomic analysis, portable sequencing instruments, the seamless integration of bioinformatics pipelines, and efficient detection of disease markers.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28281&type=smp
Which Market Drivers Are Supporting The Expansion Of The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
The expansion of the next-generation sequencing (NGS)-based molecular diagnostics market is anticipated to be fueled by the growing occurrence of infectious diseases. These conditions, caused by agents such as bacteria, viruses, fungi, or parasites, invade the body, proliferate, and disrupt normal physiological processes. The prevalence of infectious diseases is on the rise, primarily due to increased travel and migration facilitating the rapid spread of pathogens across various regions and international borders. Next-generation sequencing (NGS)-based molecular diagnostics offers a solution by enabling thorough and accurate identification of pathogens, thereby assisting in the detection of these illnesses. It shortens the time required for diagnosis by identifying multiple microorganisms concurrently, which enhances the precision of treatments and the overall standard of patient care. For example, the UK Health Security Agency reported in February 2024 that cases of tuberculosis, a highly contagious bacterial lung infection, in England climbed to 4,850 in 2023. This figure represents a 10.7% increase from the 4,380 cases recorded in 2022. Consequently, the rising incidence of infectious diseases is a key factor propelling the development of the next-generation sequencing (NGS)-based molecular diagnostics market.
Which Segment Classifications Shape The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
The next-generation sequencing (ngs)-based molecular diagnostics market covered in this report is segmented –
1) By Type: Instruments, Reagents And Consumables, Software And Services, Panels And Assays, Sample Preparation Kits
2) By Application: Microbiology, Infectious Diseases, Oncology, Genetic Tests, Other Applications
3) By End User: Research Centers And Academics, Hospitals And Clinical Laboratories, Other End Users
Subsegments:
1) By Instruments: Benchtop Sequencers, High-Throughput Sequencers, Portable Or Handheld Sequencers, Clinical Or Diagnostic Sequencers, Automated Library Preparation Systems, Data Analysis And Bioinformatics Hardware
2) By Reagents And Consumables: Sequencing Reagents And Kits, Library Preparation Reagents, Target Enrichment Reagents, Amplification Reagents, Sequencing Flow Cells And Chips, Deoxyribonucleic Acid (DNA) Or Ribonucleic Acid (RNA) Extraction Reagents, Quality Control Reagents
3) By Software And Services: Data Analysis Software, Bioinformatics Pipelines, Cloud-Based Genomic Platforms, Clinical Interpretation Tools, Data Storage And Management Services, Custom Bioinformatics Services, Genomic Database Services
4) By Panels And Assays: Oncology Panels, Infectious Disease Panels, Carrier Screening Panels, Reproductive Health Panels, Rare Disease Or Genetic Disorder Panels, Pharmacogenomics Panels, Whole-Exome Or Whole-Genome Assays
5) By Sample Preparation Kits: Deoxyribonucleic Acid (DNA) Extraction Kits, Ribonucleic Acid (RNA) Extraction Kits, Library Preparation Kits, Target Enrichment Kits, Amplification And Cleanup Kits, Single-Cell Preparation Kits, Low-Input Or Degraded Sample Kits
How Are Trends Impacting The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
Companies at the forefront of the next-generation sequencing (NGS)-based molecular diagnostics market are concentrating on developing advanced NGS-based panels to boost the accuracy, accessibility, and efficiency of genetic testing. NGS panels are specific collections of genes or genomic regions examined concurrently using NGS technology to identify clinically significant mutations for swifter and more precise molecular diagnostics. For example, in April 2024, Pillar Biosciences, a US-based diagnostics firm, gained FDA approval for its oncoReveal CDx pan-cancer solid tumor IVD kit, which assesses 22 clinically relevant genes in one multiplex reaction. This panel, designed for use with Illumina’s MiSeq Dx system, supports a sample-to-report time of approximately 48 hours and can process up to 46 clinical samples per run. OncoReveal CDx also includes companion diagnostic claims for KRAS (for EGFR-targeted therapy in colorectal cancer) and EGFR (TKI therapy in non–small-cell lung cancer), facilitating more comprehensive and efficient detection of actionable genomic alterations to enhance clinical decision-making.
Which Companies Are Expanding Their Footprint In The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market?
Major companies operating in the next-generation sequencing (ngs)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., TATAA Biocenter AB
Read the full next-generation sequencing (ngs)-based molecular diagnostics market report here:
How Is The Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Distributed Across Key Geographic Regions?
North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs)-based molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28281&type=smp
Browse Through More Reports Similar to the Global Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market 2026, By The Business Research Company
Ngs Based Rna Sequencing Market Report 2026
https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report
Next Generation Sequencing Market 2026
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-market
Point Of Care Molecular Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model